Daniela Damiani
Overview
Explore the profile of Daniela Damiani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
710
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Battaglia G, Lazzarotto D, Tanasi I, Gurrieri C, Forlani L, Mauro E, et al.
J Clin Med
. 2025 Feb;
14(3).
PMID: 39941372
: Nucleophosmin-1 () mutation accounts for 30% of acute myeloid leukemia (AML) cases and defines either low- or intermediate-risk AML, depending on -ITD mutation. New combination regimens (NCRs), adding midostaurin...
2.
Damiani D, Tiribelli M
Pharmaceuticals (Basel)
. 2025 Jan;
17(12.
PMID: 39770471
Chimeric antigen receptor (CAR) T-cell therapy represents one of the most impressive advances in anticancer therapy of the last decade. While CAR T-cells are gaining ground in various B cell...
3.
Zhao J, Cui Y, Zhou H, Zhou D, Che Z, Zhang N, et al.
Transl Cancer Res
. 2024 Dec;
13(11):6255-6272.
PMID: 39697705
Background: The use of FMS-like tyrosine kinase 3 () as a crucial target for kinase inhibitors is well established, but its association with immune infiltration remains unclear. This study aimed...
4.
Tosoni L, Morelli G, Tomadini G, Lazzarotto D, Fili C, Simeone E, et al.
Blood Cancer J
. 2024 Oct;
14(1):169.
PMID: 39353890
No abstract available.
5.
Zhang J, Qian Y, Wu Z, Li Y, Guan Y, Sun C, et al.
Transl Cancer Res
. 2024 Aug;
13(7):3783-3797.
PMID: 39145083
Background: Tyrosine kinase inhibitors (TKIs) have become the preferred drugs for the treatment of chronic phase (CP) chronic myeloid leukemia (CML). This study aims to compare the safety and efficacy...
6.
Damiani D, Tiribelli M
Biomedicines
. 2024 Jun;
12(6).
PMID: 38927401
Despite recent advances, the prognosis of acute myeloid leukemia (AML) remains unsatisfactory due to disease recurrence and the development of resistance to both conventional and novel therapies. Engineered T cells...
7.
Damiani D, Tiribelli M
Biomedicines
. 2024 Jan;
12(1).
PMID: 38255216
Despite the progress in the knowledge of disease pathogenesis and the identification of many molecular markers as potential targets of new therapies, the cure of acute myeloid leukemia remains challenging....
8.
Tosoni L, Liberi M, Morelli G, Zannier M, Lazzarotto D, Fili C, et al.
Ann Hematol
. 2023 Dec;
103(2):449.
PMID: 38157002
No abstract available.
9.
Tosoni L, Liberi M, Morelli G, Zannier M, Lazzarotto D, Fili C, et al.
Ann Hematol
. 2023 Dec;
103(2):443-448.
PMID: 38072850
Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by an increased risk of thrombotic and hemorrhagic events, that represent the leading causes of mortality and morbidity. Currently, while thrombotic risk...
10.
Wang A, Guo W, Damiani D, Sumbly V, Goyal G, Du Z, et al.
Transl Cancer Res
. 2023 Aug;
12(7):1873-1882.
PMID: 37588745
Background: B-cell prolymphocytic leukemia (B-PLL) is a rare mature B-cell tumor with an aggressive clinical course and poor prognosis. It is characterized by prominent splenomegaly and prolymphocytes exceeding 55% of...